On the heels of a strong showing for the drug earlier this year, Pfizer is padding the case for the GLP-1 receptor agonist it ...

When it comes to turning T-cell therapies toward autoimmune diseases, CAR-Ts have been leading the way. But another red-hot modality is also beginning to show potential in the clinic. | When it comes ...

Comments at the June 4 public hearing largely fell along three main fault lines—industry voiced general support for the ...

Affibody may not have expected to be working on izokibep again, but the Swedish biotech hasn’t wasted an opportunity to ...

Parabilis Medicines is gearing up for an IPO that could eventually bring in as much as $476 million to fund the phase 3 ...

A stimulator of thyroid hormone receptors in the brain has successfully reduced depression severity in patients with bipolar ...

The structural advantages that allow China to conduct clinical trials more quickly and at lower costs should be leveraged to ...

Innovent Biologics has reported a phase 3 victory for IBI343, boosting the prospects of an antibody-drug conjugate (ADC) that ...

NewLimit’s lead liver combo has proven its worth in preclinical models, Kimmel told Fierce, with the ability to boost ...

Alnylam has partnered with the person who helped put the “T” in ChatGPT, paying $30 million to work with Jakob Uszkoreit’s ...

Insulet, the diabetes device maker, debuted upgrades to its popular Omnipod 5 tubeless automated insulin delivery system. | ...

To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug ...